254 related articles for article (PubMed ID: 33374819)
21. Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension.
Gorelova A; Berman M; Al Ghouleh I
Antioxid Redox Signal; 2021 Apr; 34(12):891-914. PubMed ID: 32746619
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of pulmonary arterial hypertension and straight back syndrome in a patient with a novel BMPR2 variant affecting cytoplasmic tail domain.
Tang M; Luo J; Liu Q; Song J
Eur J Med Res; 2024 Apr; 29(1):209. PubMed ID: 38561801
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in
Tielemans B; Wagenaar A; Belge C; Delcroix M; Quarck R
Pulm Circ; 2023 Oct; 13(4):e12293. PubMed ID: 37790139
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.
Agnew C; Ayaz P; Kashima R; Loving HS; Ghatpande P; Kung JE; Underbakke ES; Shan Y; Shaw DE; Hata A; Jura N
Nat Commun; 2021 Aug; 12(1):4950. PubMed ID: 34400635
[TBL] [Abstract][Full Text] [Related]
25. 'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Swietlik EM; Prapa M; Martin JM; Pandya D; Auckland K; Morrell NW; Gräf S
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33256119
[TBL] [Abstract][Full Text] [Related]
26. A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific.
Talati M; Brittain E; Agrawal V; Fortune N; Simon K; Shay S; Zeng X; Freeman ML; West J; Hemnes A
Front Med (Lausanne); 2023; 10():1276422. PubMed ID: 37869164
[TBL] [Abstract][Full Text] [Related]
27. Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.
Mutlu Z; Kayıkçıoğlu M; Nalbantgil S; Vuran Ö; Kemal H; Moğulkoç N; Ertürk B; Onay H; Eroğlu Z; Kültürsay H
Anatol J Cardiol; 2016 Jul; 16(7):491-496. PubMed ID: 26645265
[TBL] [Abstract][Full Text] [Related]
28. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.
Eichstaedt CA; Belge C; Chung WK; Gräf S; Grünig E; Montani D; Quarck R; Tenorio-Castano JA; Soubrier F; Trembath RC; Morrell NW;
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36302552
[TBL] [Abstract][Full Text] [Related]
29. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).
Frump A; Prewitt A; de Caestecker MP
Pulm Circ; 2018; 8(2):2045894018765840. PubMed ID: 29521190
[TBL] [Abstract][Full Text] [Related]
30. Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series).
Awad KS; West JD; de Jesus Perez V; MacLean M
Pulm Circ; 2016 Sep; 6(3):285-94. PubMed ID: 27683605
[TBL] [Abstract][Full Text] [Related]
31. Human liver single nuclear RNA sequencing implicates BMPR2, GDF15, arginine, and estrogen in portopulmonary hypertension.
Jose A; Elwing JM; Kawut SM; Pauciulo MW; Sherman KE; Nichols WC; Fallon MB; McCormack FX
Commun Biol; 2023 Aug; 6(1):826. PubMed ID: 37558836
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.
Pullamsetti SS; Sitapara R; Osterhout R; Weiss A; Carter LL; Zisman LS; Schermuly RT
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628831
[TBL] [Abstract][Full Text] [Related]
33. Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.
Yu Z; Xiao J; Chen X; Ruan Y; Chen Y; Zheng X; Wang Q
Chin Med; 2022 Jan; 17(1):13. PubMed ID: 35033157
[TBL] [Abstract][Full Text] [Related]
34. BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension.
Kumar S; Biswas L; Pushkaran AC; Kumar RK
Pulm Circ; 2024 Jan; 14(1):e12335. PubMed ID: 38213946
[TBL] [Abstract][Full Text] [Related]
35. Disruption of DLL4/NOTCH1 Causes Dysregulated PPARγ/AKT Signaling in Pulmonary Arterial Hypertension.
Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
bioRxiv; 2024 Feb; ():. PubMed ID: 38903104
[TBL] [Abstract][Full Text] [Related]
36. Evolving nonvasodilator treatment options for pulmonary arterial hypertension.
Medrek S; Melendres-Groves L
Curr Opin Pulm Med; 2022 Sep; 28(5):361-368. PubMed ID: 35838352
[TBL] [Abstract][Full Text] [Related]
37. Case report: Extracorporeal life support as a successful bridge to recovery in an incident case of pulmonary arterial hypertension.
Pequignot B; Chaouat A; Chabot F; Levy B; Valentin S
Front Med (Lausanne); 2024; 11():1283065. PubMed ID: 38379558
[TBL] [Abstract][Full Text] [Related]
38. Network module-based drug repositioning for pulmonary arterial hypertension.
Wang RS; Loscalzo J
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):994-1005. PubMed ID: 34132494
[TBL] [Abstract][Full Text] [Related]
39. Whole Exome Sequence Analysis Provides Novel Insights into the Genetic Framework of Childhood-Onset Pulmonary Arterial Hypertension.
Gelinas SM; Benson CE; Khan MA; Berger RMF; Trembath RC; Machado RD; Southgate L
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33187088
[TBL] [Abstract][Full Text] [Related]
40. Case report: Pathological differences in pulmonary arterial hypertension in long-term responders to calcium channel blockers.
Tamura Y; Lkhagvadorj S; Tamura Y; Furukawa A; Aida S; Ebinuma H; Shiomi T
Front Cardiovasc Med; 2023; 10():1295718. PubMed ID: 38028466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
